ChEMBL

Here is a paper (subscription required). It is written by Lee Harland (Pfizer Regenerative Medicine) and Anna Gaulton (ex Pfizer, but now in the ChEMBL group at the EMBL-EBI). It is an overview of Drug Targets, and some of the general principles of 'druggability' and ways to assess target tractability for drug discovery. In particular, the challenges of data integration are discussed.

%A L. Harland 
%A A. Gaulton
%T Drug Target Central
%J Expert Opin. Drug. Disc.
%V 4
%P 857-872
%D 2009